17 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 22 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 17, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Recruiting 1 |
Follow Supranuclear Palsy, Progressive: new trials by email Literature Review of Supranuclear Palsy, Progressive trials Research Report on Supranuclear Palsy, Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-09-01 | 2026-10-07 |
| Test-retest Study With [18F]PI-2620 in PSP-RS and NDC [18F]-PI2620 - Progressive Supranuclear Palsy | Phase 1 | Completed | Life Molecular Imaging GmbH | 15 | 2022-03-10 | 2026-10-26 |
| Evaluation of [18F]APN-1607 as a PET Biomarker [18F] APN-1607 - Progressive Supranuclear Palsy, Healthy Volunteers | Phase 1 | Completed | Invicro | 12 | 2021-05-25 | 2025-02-20 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Tolfenamic Acid, Placebos - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Unknown | NeuroTau, Inc. | 24 | 2021-01-01 | 2020-02-05 |
| A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy UCB0107 (bepranemab) - Progressive Supranuclear Palsy | Phase 1 | Active not recruiting | UCB Biopharma SRL | 19 | 2020-11-16 | 2026-08-03 |
| Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity [18F]-PI2620 - Alzheimer Disease, Progressive Supranuclear Palsy | Phase 1 | Completed | Life Molecular Imaging GmbH | 10 | 2020-11-12 | 2026-10-26 |
| A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) bepranemab, Placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | UCB Biopharma SRL | 25 | 2019-12-03 | 2023-12-01 |
| Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 ABBV-8E12 - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | AbbVie | 3 | 2018-04-17 | 2019-12-03 |
| Phase 1 Test-retest Evaluation of [18F]MNI-958 PET [18F]MNI-958 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Completed | Invicro | 16 | 2018-03-12 | 2020-02-17 |
| Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 BIIB092 - Supranuclear Palsy, Progressive | Phase 1 | Terminated | Biogen | 47 | 2016-02-22 | 2020-05-18 |
| Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy BIIB092, Placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | Biogen | 48 | 2015-10-02 | 2018-09-04 |
| Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Single dose C2N-8E12, Single dose placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | C2N Diagnostics | 32 | 2015-07-01 | 2017-07-26 |
| Young Plasma Transfusions for Progressive Supranuclear Palsy Fresh Frozen Plasma - Progressive Supranuclear Palsy | Phase 1 | Completed | University of California, San Francisco | 6 | 2015-05-01 | 2020-08-11 |
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Salsalate - Progressive Supranuclear Palsy | Phase 1 | Completed | Adam Boxer | 10 | 2015-04-01 | 2021-04-01 |
| Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Flortaucipir F18, Brain PET scan - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 1 | Completed | Avid Radiopharmaceuticals | 29 | 2014-08-12 | 2020-08-28 |
| Safety Study of TPI-287 to Treat CBS and PSP TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS) | Phase 1 | Completed | University of California, San Francisco | 44 | 2014-05-01 | 2020-04-15 |
| Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects [18F]T807 ([18F]MNI-777) - Alzheimer's Disease (AD), Parkinson's Disease (PD) | Phase 1 | Completed | Molecular NeuroImaging | 16 | 2014-02-01 | 2016-12-16 |
| Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism stem cell therapy - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 25 | 2012-12-01 | 2013-04-04 |
| Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy alpha-lipoic acid and L-acetyl carnitine - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 11 | 2010-09-14 | 2017-05-30 |
Showing 20 of 22. Sign in to see all of them.
Corticobasal Degeneration (4) · Alzheimer Disease (3) · Pick Disease of the Brain (3) · Parkinson Disease (2) · Tauopathies (2) · Chronic Traumatic Encephalopathy (1) · Color Vision Defects (1) · Frontotemporal Dementia (1) · Frontotemporal Lobar Degeneration (1) · Multiple System Atrophy (1) · Nerve Degeneration (1) · Primary Progressive Nonfluent Aphasia (1)
Basal Ganglia Diseases (22) · Brain Diseases (22) · Central Nervous System Diseases (22) · Cranial Nerve Diseases (22) · Eye Diseases (22) · Movement Disorders (22) · Nervous System Diseases (22) · Neurodegenerative Diseases (22) · Neurologic Manifestations (22) · Ocular Motility Disorders (22) · Ophthalmoplegia (22) · Paralysis (22) · Pathological Conditions, Signs and Symptoms (22) · Signs and Symptoms (22) · Tauopathies (20)
((18)F)PI-2620 (2) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2) · florbetapir (2) · gosuranemab (2) · Acetylcarnitine (1) · Lithium (1) · Oligonucleotides, Antisense (1) · TPI-287 (1) · Thioctic Acid (1) · davunetide (1) · salicylsalicylic acid (1) · tilavonemab (1) · tolfenamic acid (1) · tributyrin (1)
University of California, San Francisco (3) · Biogen (2) · Invicro (2) · Life Molecular Imaging GmbH (2) · UCB Biopharma SRL (2) · AbbVie (1) · Adam Boxer (1) · Avid Radiopharmaceuticals (1) · C2N Diagnostics (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Molecular NeuroImaging (1) · NeuroTau, Inc. (1) · Novartis Pharmaceuticals (1) · Prabesh Kanel (1) · Weill Medical College of Cornell University (1)
United States (17) · Germany (5) · United Kingdom (4) · Belgium (2) · Spain (2) · Canada (1) · Italy (1)
Adam Boxer, MD, PhD (3) · Andrew Stephens, MD, PhD (2) · Adam L. Boxer, M.D., Ph.D. (1) · Claire Henchcliffe, MD DPhil (1) · Danna Jennings, MD (1) · David Russell, M.D., Ph. D (1) · David Russell, M.D., Ph.D. (1) · Marwan Sabbagh, MD (1) · Matthias Brendel, MD (1) · Nasser Zawia, PhD (1) · Prabesh Kanel, PhD (1)
PMID 24438512, PMID 27160012, PMID 31122495, PMID 31710340, PMID 34712113, PMID 41389437
2019 (1)